RecruitingPhase 2NCT06165419
Definitive Radiation for High-Risk Spine Metastases
A Phase II Study Evaluating Definitive Radiosurgical Decompression in Patients With High-Risk Spinal Metastases
Sponsor
Stony Brook University
Enrollment
26 participants
Start Date
Dec 14, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
This study is looking at whether patients with cancer that has aggressively spread to the spine can be treated with stereotactic body radiation therapy only and avoid a large spine surgery
Eligibility
Min Age: 18 Years
Inclusion Criteria11
- Eligible patients must have:
- Any pathologically proven solid tumor diagnosis not of central nervous system origin with radiographic or pathologic evidence of metastatic disease
- Metastatic spine involvement documented by imaging
- Involvement of maximum 3 contiguous vertebral bodies at the index site
- Intact neurologic function, or only minor neurologic deficits with muscle strength greater or equal to 4 out of 5 with or without steroids
- An evaluation by an radiation oncology and orthopedic spine/neurosurgery attending
- ECOG Performance Status of 0-3
- Patients are ineligible if they have:
- An unstable spine defined as a Spinal Instability Neoplastic Score (SINS) greater than 12
- Had previous surgery or radiation to address the target spinal metastases
- Radiosensitive tumors (e.g. small cell lung cancer, lymphoma, multiple myeloma, and germ-cell tumors)
Interventions
RADIATIONSBRT to the spine
Stereotactic body radiation therapy (SBRT) administered to spine metastases
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06165419
Related Trials
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892139 locations
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
NCT066493311 location
Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)
NCT059645044 locations
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
NCT0342400545 locations
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT0708576735 locations